[Study of therpaeutic indications of Ro 4-8347].
D000568:Amenorrhea / Q000188:drug therapy; D000738:Androsterone / Q000652:urine*; D001831:Body Temperature / Q000187:drug effects; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D003864:Depression, Chemical; D004967:Estrogens / Q000652:urine*; D005043:Etiocholanolone / Q000652:urine*; D005260:Female; D005306:Fertilization / Q000187:drug effects*; D006801:Humans; D008297:Male; D008599:Menstruation Disturbances / Q000188:drug therapy*; D008796:Metrorrhagia / Q000139:chemically induced; D010060:Ovulation / Q000187:drug effects*; D011247:Pregnancy; D011276:Pregnanediol / Q000652:urine*; D011372:Progestins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013268:Stimulation, Chemical
D006063:Chorionic Gonadotropin; D004967:Estrogens; D011372:Progestins; D005043:Etiocholanolone; D000738:Androsterone; D011276:Pregnanediol
Etude des indications thérapeutiques du Ro 4-8347.